On 20 Nov 2025, Sarda Proteins opened with a gap down of 4.47%, settling at Rs.63.06, which also represented the day's low. The stock has traded at this level throughout the session, showing no intraday range movement. This price point is notably below its 5-day, 20-day, 50-day, and 100-day moving averages, although it remains above the 200-day moving average, indicating a complex technical picture.
In comparison, the Sensex opened 284.45 points higher and is currently trading at 85,632.68, a new 52-week high, supported by strong performances from mega-cap stocks. The index is positioned above its 50-day moving average, which itself is above the 200-day moving average, signalling a bullish trend in the broader market. This divergence highlights the challenges faced by Sarda Proteins within its sector and the market at large.
Over the past year, Sarda Proteins has recorded a return of -41.53%, significantly underperforming the Sensex, which has shown a positive return of 10.38% during the same period. The stock's 52-week high was Rs.137.45, underscoring the extent of the decline to the current low.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
The edible oil sector, to which Sarda Proteins belongs, has generally experienced mixed results, but the stock's performance has been notably weaker. The company has not declared financial results in the last six months, which adds to the uncertainty surrounding its current valuation. Its ability to service debt is under pressure, with an average EBIT to interest ratio of 0.01, reflecting limited earnings before interest and taxes relative to interest obligations.
Financially, Sarda Proteins has reported losses, contributing to a negative return on equity (ROE). The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) have been negative, which is a key factor in the stock's risk profile. Over the past year, profits have declined by approximately 5%, further weighing on investor confidence.
In terms of trading activity, the stock has shown erratic behaviour, having not traded on one day out of the last 20 trading sessions. This irregularity may reflect lower liquidity or investor hesitation. Additionally, the stock underperformed its sector by 4.8% today, indicating relative weakness compared to peers.
Long-term performance metrics also paint a challenging picture. Sarda Proteins has underperformed the BSE500 index over the last three years, one year, and three months, suggesting persistent difficulties in generating returns relative to a broad market benchmark.
Considering Sarda Proteins ? Wait! SwitchER has found potentially better options in Edible Oil and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Edible Oil + beyond scope
- - Top-rated alternatives ready
Despite the recent challenges, the company reported positive results in June 2025, with net sales for the half-year period reaching ₹109.55 million, reflecting a growth rate of 18,127.29%. This sharp increase in sales, however, has not yet translated into profitability or improved financial stability.
In summary, Sarda Proteins' stock has reached a critical low point at Rs.63.06, reflecting a combination of weak financial metrics, negative earnings, and underperformance relative to both sector and market indices. While the broader market and edible oil sector show signs of strength, the company’s current financial and trading indicators suggest ongoing challenges.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
